The cochairs of the AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers—Andrew Futreal, PhD, FAACR, of The University of Texas MD Anderson Cancer Center; Taran Gujral, PhD, of Fred Hutch...
Can AI agents do cancer research? Many AI-centric research teams currently believe that with the right training, AI agents can in fact rise to the level of “co-scientists,” including Jure Leskovec, PhD, of Stanford...
Chenia Lloyd-Gascho, who was diagnosed with Li-Fraumeni syndrome when he was 8 years old, shared what it is like to grow up knowing you will one day get cancer, the routine monitoring recommended to...
AACR grant recipient Tae Hyun Hwang, PhD, of Vanderbilt University Medical Center, presented his work at the AACR Annual Meeting 2026 on AI agents that work together to assess how patients could respond to therapy and aid doctors in making cancer treatment decisions.
A targeted therapy nearly doubles overall survival in metastatic pancreatic cancer, and the FDA approves a bladder cancer treatment.
At the AACR Annual Meeting 2026, Lillian Siu shared her research into cancer interception and assembled a panel to discuss targeted cancer prevention.
At the AACR Annual Meeting 2026, researchers discussed the use of vaccines and aspirin to prevent cancer in people with Lynch syndrome.
In May, AACR's journals editors highlighted studies on CD28’s impact on CAR T-cell activity, the relationship between neurons and pancreatic cancer, and more.
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
A recent analysis examined whether CYP2D6 metabolism influences tamoxifen response. The answer isn’t entirely clear.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More